Immunotherapy has rapidly gained popularity in recent years. These approaches have the potential to reduce safety concerns, have a higher therapeutic index and tackle a breadth of targets including solid tumors. With the advent of these promising therapies, the field of oncology continues to evolve quickly and calls for novel approaches to clinical trials. Staying competitive in this increasingly crowded field will require sponsors to adopt nontraditional, flexible trial designs to enhance cost efficiency and reduce patient burden.

What Our Clients Say

Find out how our research experts can help with your next study or program.